BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, the first-generation BTK inhibitor, was approved for treating B cell malignancies including chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinema [66].